(Q33294185)

25 July 2017

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema (English)

1 reference

25 July 2017

phase II clinical trial

0 references

bevacizumab

1 reference

inferred from title

diabetic macular edema

1 reference

Diabetic Retinopathy Clinical Research Network

inferred from title

author

1

object named as

Diabetic Retinopathy Clinical Research Network

1 reference

25 July 2017

2

Ingrid U Scott

1 reference

25 July 2017

5

Neil M Bressler

1 reference

25 July 2017

4

Roy W Beck

1 reference

25 July 2017

Allison R Edwards

3

1 reference

25 July 2017

Clement K Chan

6

1 reference

25 July 2017

Michael J Elman

7

1 reference

25 July 2017

Scott M Friedman

8

1 reference

25 July 2017

Craig Michael Greven

9

1 reference

25 July 2017

Raj K Maturi

10

1 reference

25 July 2017

Dante J Pieramici

11

1 reference

25 July 2017

Michel Shami

12

1 reference

25 July 2017

Lawrence J Singerman

13

1 reference

25 July 2017

Cynthia R Stockdale

14

1 reference

25 July 2017

15 August 2007

1 reference

25 July 2017

1 reference

25 July 2017

114

1 reference

25 July 2017

10

1 reference

25 July 2017

1860-1867

1 reference

Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema.

25 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Ranibizumab for neovascular age-related macular degeneration

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Variability of full-field electroretinogram responses in subjects without diffuse photoreceptor cell disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Intravitreal triamcinolone for refractory diabetic macular edema

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2245885

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

31 October 2018

1 reference

12 December 2020

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

1 reference

12 December 2020

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized cl

1 reference

12 December 2020

Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment

1 reference

12 December 2020

10.1016/J.OPHTHA.2007.05.062

Identifiers

DOI

1 reference

25 July 2017

1 reference

25 July 2017

1 reference